No Data
No Data
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solu
Alight, Novavax, and More Stocks See Action From Activist Investors
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from May 2 through May 8, 2024. Source: VerityData
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
4 analysts have shared their evaluations of PROCEPT BioRobotics (NASDAQ:PRCT) during the recent three months, expressing a mix of bullish and bearish perspectives.In the table below, you'll find a sum
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
Express News | Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75